Zura Bio Statistics
Total Valuation
Zura Bio has a market cap or net worth of $356.24 million. The enterprise value is $130.65 million.
| Market Cap | 356.24M |
| Enterprise Value | 130.65M |
Important Dates
The last earnings date was Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Zura Bio has 95.00 million shares outstanding. The number of shares has increased by 14.31% in one year.
| Current Share Class | 95.00M |
| Shares Outstanding | 95.00M |
| Shares Change (YoY) | +14.31% |
| Shares Change (QoQ) | +18.36% |
| Owned by Insiders (%) | 11.03% |
| Owned by Institutions (%) | 53.54% |
| Float | 50.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.64 |
| P/TBV Ratio | 1.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.33
| Current Ratio | 19.33 |
| Quick Ratio | 19.21 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -40.96% and return on invested capital (ROIC) is -27.66%.
| Return on Equity (ROE) | -40.96% |
| Return on Assets (ROA) | -25.39% |
| Return on Invested Capital (ROIC) | -27.66% |
| Return on Capital Employed (ROCE) | -37.57% |
| Weighted Average Cost of Capital (WACC) | 4.41% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.65M |
| Employee Count | 40 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +228.95% in the last 52 weeks. The beta is 0.03, so Zura Bio's price volatility has been lower than the market average.
| Beta (5Y) | 0.03 |
| 52-Week Price Change | +228.95% |
| 50-Day Moving Average | 4.63 |
| 200-Day Moving Average | 4.64 |
| Relative Strength Index (RSI) | 41.73 |
| Average Volume (20 Days) | 954,263 |
Short Selling Information
The latest short interest is 6.22 million, so 6.55% of the outstanding shares have been sold short.
| Short Interest | 6.22M |
| Short Previous Month | 6.24M |
| Short % of Shares Out | 6.55% |
| Short % of Float | 12.23% |
| Short Ratio (days to cover) | 9.28 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -81.49M |
| Pretax Income | -75.43M |
| Net Income | -106.13M |
| EBITDA | -81.44M |
| EBIT | -81.49M |
| Earnings Per Share (EPS) | -$1.07 |
Balance Sheet
The company has $225.59 million in cash and n/a in debt, with a net cash position of $225.59 million or $2.37 per share.
| Cash & Cash Equivalents | 225.59M |
| Total Debt | n/a |
| Net Cash | 225.59M |
| Net Cash Per Share | $2.37 |
| Equity (Book Value) | 216.90M |
| Book Value Per Share | 2.28 |
| Working Capital | 215.26M |
Cash Flow
In the last 12 months, operating cash flow was -$72.68 million and capital expenditures -$77,000, giving a free cash flow of -$72.75 million.
| Operating Cash Flow | -72.68M |
| Capital Expenditures | -77,000 |
| Depreciation & Amortization | 56,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -72.75M |
| FCF Per Share | -$0.77 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Zura Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.31% |
| Shareholder Yield | -14.31% |
| Earnings Yield | -29.79% |
| FCF Yield | -20.42% |
Analyst Forecast
The average price target for Zura Bio is $15.67, which is 317.87% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.67 |
| Price Target Difference | 317.87% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |